MODERATE-TO-SEVERE ATOPIC DERMATITIS
Clinical trials for MODERATE-TO-SEVERE ATOPIC DERMATITIS explained in plain language.
Never miss a new study
Get alerted when new MODERATE-TO-SEVERE ATOPIC DERMATITIS trials appear
Sign up with your email to follow new studies for MODERATE-TO-SEVERE ATOPIC DERMATITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New injection shows promise for tough eczema in early trial
Disease control Not yet recruitingThis Phase 2 study tests a new biologic drug called AK139 in 168 adults with moderate-to-severe atopic dermatitis (eczema) that hasn't improved with creams. Participants will receive either AK139 or a placebo by injection. The study aims to see if AK139 can safely clear skin and …
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New eczema pill shows promise in early trial
Disease control Not yet recruitingThis Phase 2 trial tests an experimental drug called CMS-D001 in 160 adults with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. Participants will take one of three doses of the drug or a placebo daily for several weeks. The main goal is to see…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Dermavon Holdings Limited • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New pill could ease severe eczema in major trial
Symptom relief Not yet recruitingThis phase 3 study tests an oral tablet called LW402 in 480 adults with moderate-to-severe atopic dermatitis (eczema). Participants will take either the drug or a placebo daily for 16 weeks. The goal is to see if LW402 can significantly improve eczema severity and skin clearance …
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE3 • Sponsor: Shanghai Longwood Biopharmaceuticals Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
New eczema pill aims to calm angry skin
Symptom relief Not yet recruitingThis study tests an experimental capsule called QLS12010 in 160 adults with moderate-to-severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and rash better than a placebo over 16 weeks. Participants must have had eczema for at least one year…
Matched conditions: MODERATE-TO-SEVERE ATOPIC DERMATITIS
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Symptom relief
Last updated Jun 27, 2026 08:11 UTC